- Home
- / Novo Nordisk
Novo Nordisk
Stock Price
KR921.5
2024-08-22
Market Capitalization
KR4.1 T
2024-08-22
Revenue
KR232.3 B
FY, 2023
Novo Nordisk Summary
Company Summary
- Overview
- Novo Nordisk is a healthcare company that designs and manufactures pharmaceutical products. It operates through two segments: Diabetes and Obesity care and Biopharm. The Diabetes and Obesity care segment covers insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment covers the therapy areas of haemophilia, growth disorders, and hormone replacement therapy.
- Type
- Public
- Status
- Active
- Founded
- 1923
- HQ
- Bagsværd, DK | view all locations
- Website
- https://www.novonordisk.com/
- Cybersecurity rating
- ESG rating
- Sectors
Table of Contents
Key People
Monique Carter, Executive Vice President and Head of People & Organisation
Maziar Mike Doustdar, Executive Vice President and Head of International Operations
Ludovic Helfgott, Executive Vice President and Head of Rare Disease
Operating MetricsView all
Phase I Trials Products (Haemophilia)
1
Q4, 2021
Trials Products Approved (Obesity)
2
Q3, 2022
Phase III Trials Products (Obesity)
2
100.0%
Q3, 2022
LocationsView all
109 locations detected
Bagsværd HQ
Denmark
Novo Allé 1
Cambridge, MA
United States
255 Main St #10th
Clayton, NC
United States
3612 Powhatan Rd
Durham, NC
United States
5235 International Dr
Fremont, CA
United States
6300 Dumbarton Cir
Indianapolis, IN
United States
5225 Exploration Dr
Novo Nordisk Financials
Summary Financials
- Revenue (Q1, 2024)
- kr65.3B
- Gross profit (Q1, 2024)
- kr58.3B
- Net income (Q1, 2024)
- kr25.4B
- Cash (Q1, 2024)
- kr6.3B
- EBIT (Q1, 2024)
- kr31.8B
- Enterprise value
- $4.0T